<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798160</url>
  </required_header>
  <id_info>
    <org_study_id>SIRT-TACE-HCC-Mainz-1</org_study_id>
    <nct_id>NCT01798160</nct_id>
  </id_info>
  <brief_title>Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).</brief_title>
  <official_title>Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selective Internal Radiation Therapy is superior to Transarterial Chemoembolisation for the
      treatment of intermediate stage hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free-Survival</measure>
    <time_frame>up to three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall-Survival</measure>
    <time_frame>up to three years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>DEB TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug eluting Beads (DC Beads) loaded with Doxorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DEB TACE</intervention_name>
    <description>DEB TACE every 6 weeks until either no viable tumor or endpoint reached.</description>
    <arm_group_label>DEB TACE</arm_group_label>
    <other_name>Chemoembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SIRT</intervention_name>
    <description>Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.</description>
    <arm_group_label>SIRT</arm_group_label>
    <other_name>Radioembolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years

          -  HCC, proven by histology or according to EASL criteria

          -  Intermediate stage HCC (stage B according to BCLC)

          -  At least one measurable lesion in magnetic resonance imaging (MRI)

          -  Tumor load ≤ 50%

          -  preserved liver function (Child Pugh A and B)

        Exclusion Criteria:

          -  Patients feasible for curative treatment (e.g. resection or local ablation)

          -  Previous TACE or SIRT

          -  Chemotherapy during the last 4 weeks

          -  Child Pugh stage C

          -  BCLC stage D

          -  ECOG Performance Status &gt;0

          -  Tumor involvement &gt;50% of the liver

          -  Extrahepatic tumor

          -  Serum Bilirubin &gt;2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine &gt;2 mg/dl;
             Leukocytes &lt;3000/ml; Thrombocytes &lt;50000/ml

          -  Clinically apparent ascites (ascites only in CT/MRI is no exclusion criteria)

          -  Esophageal bleeding during the last 3 months

          -  Hepatic encephalopathy

          -  Transjugular intrahepatic portosystemic shunt (TIPS)

          -  Infiltration or occlusion of the portal vein

          -  Hepatofugal blood flow in the portal vein

          -  Hepatopulmonary shunt ≥ 20% in the macroaggregated albumin scan

          -  Contraindications against angiography

          -  Gravidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>October 18, 2015</last_update_submitted>
  <last_update_submitted_qc>October 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Michael Bernhard Pitton</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

